CN107427549B - 用于抑制血管生成的肽 - Google Patents

用于抑制血管生成的肽 Download PDF

Info

Publication number
CN107427549B
CN107427549B CN201680012874.6A CN201680012874A CN107427549B CN 107427549 B CN107427549 B CN 107427549B CN 201680012874 A CN201680012874 A CN 201680012874A CN 107427549 B CN107427549 B CN 107427549B
Authority
CN
China
Prior art keywords
hours
peptide
neovascularization
vegf
retinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680012874.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107427549A (zh
Inventor
Y.A.科马洛娃
M.罗森布拉特
A.B.马利克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN107427549A publication Critical patent/CN107427549A/zh
Application granted granted Critical
Publication of CN107427549B publication Critical patent/CN107427549B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00844—Feedback systems
    • A61F2009/00851—Optical coherence topography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00863—Retina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00865—Sclera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00872—Cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201680012874.6A 2015-03-02 2016-03-02 用于抑制血管生成的肽 Expired - Fee Related CN107427549B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126968P 2015-03-02 2015-03-02
US62/126,968 2015-03-02
PCT/US2016/020443 WO2016141053A1 (en) 2015-03-02 2016-03-02 Peptides for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
CN107427549A CN107427549A (zh) 2017-12-01
CN107427549B true CN107427549B (zh) 2022-01-11

Family

ID=55543089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680012874.6A Expired - Fee Related CN107427549B (zh) 2015-03-02 2016-03-02 用于抑制血管生成的肽

Country Status (18)

Country Link
US (2) US9675660B2 (enExample)
EP (1) EP3265110B1 (enExample)
JP (1) JP6896641B2 (enExample)
KR (1) KR20170122762A (enExample)
CN (1) CN107427549B (enExample)
AU (1) AU2016226264B2 (enExample)
BR (1) BR112017018665A2 (enExample)
CA (1) CA2977389A1 (enExample)
DK (1) DK3265110T3 (enExample)
ES (1) ES2820710T3 (enExample)
IL (1) IL253966B (enExample)
MX (1) MX2017011170A (enExample)
PH (1) PH12017501549B1 (enExample)
PL (1) PL3265110T3 (enExample)
RU (1) RU2708375C2 (enExample)
SG (1) SG11201706799YA (enExample)
WO (1) WO2016141053A1 (enExample)
ZA (1) ZA201705934B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112169A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
US20220054583A1 (en) * 2018-09-11 2022-02-24 Anbition S.R.L. Peptides and medical uses thereof
CN113755634A (zh) * 2021-10-12 2021-12-07 河南省农业科学院烟草研究所 一种鸢尾丝囊霉菌分子检测的特异引物及其检测方法
CN115737677B (zh) * 2022-07-25 2024-09-06 天津医科大学总医院 一种多肽修饰的金纳米颗粒在制备抑制糖尿病视网膜病变药物中的用途
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015385A2 (en) * 2004-08-06 2006-02-09 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
CN102286101A (zh) * 2011-08-08 2011-12-21 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
AU2004285562B2 (en) * 2003-10-29 2011-06-09 The Johns Hopkins University Pigment epithelium-derived factor, novel biological activity and methods of use
EP1689355A4 (en) 2003-11-06 2008-10-01 Res Dev Foundation SELECTIVE INHIBITORS OF NUCLEAR FACTOR KB ACTIVATION AND ITS USES
AU2008296733B2 (en) * 2007-08-08 2013-07-11 The Board Of Regents Of The University Of Texas System VEGFR-1/NRP-1 targeting peptides
CA2693001A1 (en) * 2008-04-16 2009-10-22 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
EP2439514A1 (en) 2010-10-01 2012-04-11 Aqsens Oy Method, apparatus, and system for examining optically a sample carried in a plurality of wells
US9248198B2 (en) 2011-06-13 2016-02-02 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015385A2 (en) * 2004-08-06 2006-02-09 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
CN102286101A (zh) * 2011-08-08 2011-12-21 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用

Also Published As

Publication number Publication date
RU2017133101A (ru) 2019-04-02
US9675660B2 (en) 2017-06-13
US20170258868A1 (en) 2017-09-14
EP3265110A1 (en) 2018-01-10
JP6896641B2 (ja) 2021-06-30
HK1248101A1 (zh) 2018-10-12
MX2017011170A (es) 2018-04-24
CN107427549A (zh) 2017-12-01
AU2016226264B2 (en) 2021-04-01
RU2708375C2 (ru) 2019-12-06
HK1247573A1 (zh) 2018-09-28
ZA201705934B (en) 2018-12-19
IL253966B (en) 2019-12-31
JP2018508528A (ja) 2018-03-29
ES2820710T3 (es) 2021-04-22
RU2017133101A3 (enExample) 2019-07-26
CA2977389A1 (en) 2016-09-09
EP3265110B1 (en) 2020-07-15
PH12017501549B1 (en) 2021-12-15
BR112017018665A2 (pt) 2018-04-24
DK3265110T3 (da) 2020-10-19
IL253966A0 (en) 2017-10-31
PL3265110T3 (pl) 2020-12-28
PH12017501549A1 (en) 2018-02-05
KR20170122762A (ko) 2017-11-06
SG11201706799YA (en) 2017-09-28
US10064911B2 (en) 2018-09-04
AU2016226264A1 (en) 2017-08-31
US20160256518A1 (en) 2016-09-08
WO2016141053A1 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
CN107427549B (zh) 用于抑制血管生成的肽
AU2016241499B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
AU2015226911A1 (en) Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
JP7269649B2 (ja) Ｋｉｆ１３ｂ由来ペプチドおよび血管新生阻害方法
ES2713068T3 (es) Derivados de IGFBP-3 y usos de los mismos
JP2020518678A (ja) ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
ES2729970T3 (es) Péptidos derivados de neuropéptidos y
KR101493775B1 (ko) 맥락막 신생혈관용 백신 치료
JP7650074B2 (ja) 眼疾患を治療するための組成物及び方法
AU2019337806B2 (en) Peptides and medical uses thereof
HK1247573B (zh) 用於抑制血管生成的肽
HK1248101B (en) Peptides for inhibiting angiogenesis
EP4454705A1 (en) Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of retinal pigment epithelium (rpe) cells
WO2025056713A1 (en) Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (rpe) cells
EP4153209A1 (en) Method for treating lysosomal storage diseases with histatin peptides
HK40030406A (en) Methods of treatment and novel constructs
CN111201247A (zh) 治疗方法和新颖构建体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247573

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220111